ArticleChest2025
Inflammatory and Mucociliary Dysfunction-Based Endotypes Across the Spectrum of Chronic Airway Diseases.
Article in Chest, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- The role of the respiratory microbiome in acute and chronic respiratory diseases.Nature reviews. Microbiology · 2026Review
- Review
- Microbiome and its role in bronchiectasis.Therapeutic advances in respiratory diseaseReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThere is substantial overlap between features of COPD, asthma, bronchiectasis, and cystic fibrosis (CF). Each is characterized by inflammation and mucociliary dysfunction. RESEARCH QUESTION: Is there a relationship between inflammation and mucociliary clearance in chronic respiratory conditions, and can biology, rather than disease labels, stratify patients into therapeutically relevant subtypes? STUDY DESIGN AND
methodsPatients were categorized according to primary disease and clinical characteristics recorded. Spontaneous sputum was collected, and inflammatory markers (neutrophil elastase and 18 cytokines), sputum properties (DNA content, mucins, rheology, dry weight), and microbiome (long-read 16S sequencing) were measured. K-means clustering was performed and parameters compared between and within disease groups. Control participants were individuals who had formerly smoked but were without respiratory disease.
resultsThe study included patients with asthma (n = 76), COPD (n = 91), bronchiectasis (n = 54), CF (n = 24), and control participants (n = 26). Nine cytokines (interferon-γ, IL-4, IL-5, eotaxin, eotaxin-3, thymus and activation regulated chemokine, granulocyte colony-stimulating factor, fractalkine, IL-22), neutrophil elastase, dry weight, mucins, and sputum rheology parameters were significantly different between disease groups and control participants (P < .05). K-means clustering identified 2 clusters defined by neutrophilic or T helper 2 (Th2) inflammation. The Th2 cluster was associated with lower sputum dry weight and DNA content and higher mucin-5B. Rheological parameters G', G'', and G∗ were significantly higher in the Th2 group, whereas the tangent of the loss angle δ was higher in the neutrophilic group, indicating a higher viscous to elastic ratio (P < .05 all comparisons). The neutrophilic cluster was associated with decreased alpha diversity (P = .04) and increased presence of Proteobacteria in their sputum microbiome compared with the Th2 cluster (P = .01). More neutrophilic inflammation was present in CF and bronchiectasis (42% of patients with COPD and 46% of patients with asthma were neutrophilic vs 78% of bronchiectasis and 87% of CF (P < .0001). Both clusters were present in all disease groups.
interpretationOur results indicate that airway diseases have heterogeneous mucus properties. Patients were shown to cluster according to inflammatory endotype rather than disease label. Assessment based on disease labels may be aided by endotyping using inflammatory and mucociliary clearance biomarkers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.